Skip to content

Maternal Epidural Steroids and Hyperthemia

Maternal Epidural Steroids to Prevent Neonatal Exposure to Hyperthermia and Inflammation

Status
Terminated
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02212210
Enrollment
135
Registered
2014-08-08
Start date
2012-02-29
Completion date
2015-10-31
Last updated
2017-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication of Anesthesia During Pregnancy, Unspecified, Fever, Labor Pain

Brief summary

The purpose of this study is to look to see if adding steroids to an epidural reduces the chances of having a fever in labor, and protects the baby from exposure to inflammation.

Detailed description

The association between epidural analgesia and increased maternal intrapartum temperature has been well documented in multiple randomized controlled trials. The exact mechanism for this elevation in temperature is unknown; however the most likely cause appears to be non-infectious inflammatory stimulation. Fetal exposure to maternal fever in utero has been linked with increased antibiotic treatment, increased neonatal sepsis evaluation, and longer length of stay for neonates. In addition there is evidence to suggest intrapartum fevers may lower the threshold for fetal hypoxic brain injury and increase the risk of cerebral palsy. The risk of neonatal encephalopathy in infants born to febrile mothers is 1% compared to 0.1% to afebrile mothers. Safe interventions are needed to prevent adverse fetal outcomes.

Interventions

DRUGMethylprednisolone
DRUGNormal saline

Sponsors

Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Nulliparity * Age\>=18 * Patient requests epidural analgesia * GA \>= 37 weeks

Exclusion criteria

* No prenatal care * Temperature \>99.4 at decision for epidural placement * Cervical dilation \>4cm * Diabetes (pre-gestational or gestational) * Autoimmune condition * Pre-eclampsia * Maternal heart disease * Current steroid use * Active infection (bacterial or viral) * Wet Tap (CSF on placement of epidural) * Pre-gestational diabetes * Known systemic infection (bacterial, viral, fungal or tubercular) * Known allergy to steroids * Heart failure * Hypertensive crisis * History of active epilepsy

Design outcomes

Primary

MeasureTime frameDescription
Rate of maternal feverdeliveryOral maternal temperature will be collected hourly starting at epidural placement. Temperature will be recorded until delivery.

Secondary

MeasureTime frameDescription
Rate of funisitisdeliveryCord segment will be collected at time of delivery and fetal end identified and sent to pathologist for evidence of funisitis, grade and stage.

Other

MeasureTime frameDescription
IL-6 leveldeliveryCord blood will be obtained at delivery and plasma will be assessed for IL-\^ levels by standard ELISA.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026